Cardiol Therapeutics (CRDL) News Today $1.82 -0.04 (-2.15%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech IndexNovember 13, 2024 | globenewswire.comCardiol Therapeutics (NASDAQ:CRDL) versus IN8bio (NASDAQ:INAB) Critical ReviewNovember 9, 2024 | americanbankingnews.comCardiol Therapeutics Inc. (NASDAQ:CRDL) Sees Large Increase in Short InterestCardiol Therapeutics Inc. (NASDAQ:CRDL - Get Free Report) saw a significant increase in short interest in the month of October. As of October 15th, there was short interest totalling 991,600 shares, an increase of 39.6% from the September 30th total of 710,500 shares. Based on an average trading volume of 414,900 shares, the days-to-cover ratio is presently 2.4 days. Currently, 1.5% of the shares of the company are sold short.October 30, 2024 | marketbeat.comHC Wainwright Issues Negative Outlook for CRDL EarningsCardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Analysts at HC Wainwright reduced their Q3 2024 EPS estimates for Cardiol Therapeutics in a research report issued to clients and investors on Thursday, October 24th. HC Wainwright analyst V. Bernardino now anticipates that the company willOctober 28, 2024 | marketbeat.comCardiol Therapeutics (NASDAQ:CRDL) Rating Reiterated by HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $9.00 price objective on shares of Cardiol Therapeutics in a research report on Thursday.October 24, 2024 | marketbeat.comCardiol Therapeutics’ Strategic Advancements Boost Market Potential and Revenue ProjectionsOctober 24, 2024 | markets.businessinsider.comCardiol Therapeutics (CRDL) Gets a Buy from Roth MKMOctober 24, 2024 | markets.businessinsider.comAre Medical Stocks Lagging Cardiol Therapeutics (CRDL) This Year?October 22, 2024 | msn.comCardiol Therapeutics to expand clinical program for recurrent pericarditis with MAVERIC-2 trialOctober 22, 2024 | proactiveinvestors.comWholesale inflation remained cool last month in latest sign that price pressures are slowingOctober 12, 2024 | ca.finance.yahoo.comCardiol Therapeutics raises $15.5M following over-allotment option exerciseOctober 11, 2024 | proactiveinvestors.comCardiol Therapeutics prices $13.5M public offeringOctober 9, 2024 | proactiveinvestors.comCardiol Therapeutics reaches target enrollment for Phase II acute myocarditis trialSeptember 24, 2024 | proactiveinvestors.comCardiol Therapeutics (CRDL) Upgraded to Buy: Here's WhySeptember 13, 2024 | msn.comRoth Capital Analysts Boost Earnings Estimates for Cardiol Therapeutics Inc. (NASDAQ:CRDL)Cardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Stock analysts at Roth Capital upped their Q3 2024 earnings per share (EPS) estimates for Cardiol Therapeutics in a note issued to investors on Tuesday, September 10th. Roth Capital analyst J. Wittes now forecasts that the company will postSeptember 13, 2024 | marketbeat.comStocks in play: Cardiol Therapeutics IncSeptember 11, 2024 | ca.finance.yahoo.comCardiol Therapeutics to unveil data from Phase 2 recurrent pericarditis studySeptember 10, 2024 | proactiveinvestors.comCardiol Therapeutics Inc. (NASDAQ:CRDL) Given Consensus Rating of "Buy" by BrokeragesShares of Cardiol Therapeutics Inc. (NASDAQ:CRDL - Get Free Report) have earned an average rating of "Buy" from the six brokerages that are currently covering the firm, MarketBeat.com reports. Five analysts have rated the stock with a buy recommendation and one has given a strong buy recommendatioSeptember 9, 2024 | marketbeat.comCardiol Therapeutics Inc. (NASDAQ:CRDL) Receives Consensus Recommendation of "Buy" from BrokeragesShares of Cardiol Therapeutics Inc. (NASDAQ:CRDL - Get Free Report) have been assigned a consensus rating of "Buy" from the six analysts that are presently covering the firm, MarketBeat.com reports. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy raAugust 15, 2024 | marketbeat.comCardiol Therapeutics Inc. (NASDAQ:CRDL) Receives Consensus Recommendation of "Buy" from AnalystsShares of Cardiol Therapeutics Inc. (NASDAQ:CRDL - Get Free Report) have received a consensus recommendation of "Buy" from the seven research firms that are covering the firm, Marketbeat.com reports. Six investment analysts have rated the stock with a buy recommendation and one has issued a stronJuly 21, 2024 | marketbeat.comQ2 2024 EPS Estimates for Cardiol Therapeutics Inc. Reduced by Roth Capital (NASDAQ:CRDL)Cardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Investment analysts at Roth Capital dropped their Q2 2024 earnings per share estimates for Cardiol Therapeutics in a report released on Tuesday, July 16th. Roth Capital analyst J. Wittes now expects that the company will post earnings of ($0July 18, 2024 | marketbeat.comCardiol Therapeutics Inc. (NASDAQ:CRDL) Sees Large Growth in Short InterestCardiol Therapeutics Inc. (NASDAQ:CRDL - Get Free Report) was the recipient of a significant growth in short interest during the month of June. As of June 15th, there was short interest totalling 776,300 shares, a growth of 107.6% from the May 31st total of 374,000 shares. Based on an average trading volume of 501,700 shares, the days-to-cover ratio is presently 1.5 days. Currently, 1.2% of the company's stock are sold short.June 28, 2024 | marketbeat.comCardiol Therapeutics (NASDAQ:CRDL) Receives New Coverage from Analysts at Roth MkmRoth Mkm assumed coverage on Cardiol Therapeutics in a research report on Wednesday. They set a "buy" rating and a $10.00 price target on the stock.June 26, 2024 | marketbeat.comShort Interest in Cardiol Therapeutics Inc. (NASDAQ:CRDL) Grows By 40.3%Cardiol Therapeutics Inc. (NASDAQ:CRDL - Get Free Report) was the recipient of a large growth in short interest in May. As of May 31st, there was short interest totalling 374,000 shares, a growth of 40.3% from the May 15th total of 266,500 shares. Currently, 0.6% of the shares of the stock are short sold. Based on an average trading volume of 360,800 shares, the short-interest ratio is presently 1.0 days.June 16, 2024 | marketbeat.comCardiol Therapeutics (NASDAQ:CRDL) Receives Buy Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and set a $9.00 target price on shares of Cardiol Therapeutics in a research report on Friday.June 14, 2024 | marketbeat.comCardiol Therapeutics releases Phase II data showing CardiolRx reduces pericarditis pain and inflammationJune 13, 2024 | proactiveinvestors.comCardiol Therapeutics (NASDAQ:CRDL) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $9.00 target price on shares of Cardiol Therapeutics in a report on Friday.June 7, 2024 | marketbeat.comClosing Bell: Cardiol Therapeutics Inc Purchase WT flat on Friday (CRDL-WT-A)May 22, 2024 | theglobeandmail.comCardiol Therapeutics Inc Class A (CRDL)May 22, 2024 | investing.comCRDL Stock Earnings: Cardiol Therapeutics Meets EPS for Q1 2024May 14, 2024 | investorplace.comCardiol Therapeutics surpasses 85% enrollment in ARCHER trial for acute myocarditisMay 14, 2024 | proactiveinvestors.comCardiol Therapeutics Inc. (NASDAQ:CRDL) Forecasted to Earn Q1 2024 Earnings of ($0.06) Per ShareCardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Stock analysts at HC Wainwright issued their Q1 2024 earnings per share (EPS) estimates for Cardiol Therapeutics in a research report issued to clients and investors on Monday, April 22nd. HC Wainwright analyst V. Bernardino expects that theApril 24, 2024 | marketbeat.comCardiol Therapeutics (NASDAQ:CRDL) Coverage Initiated by Analysts at HC WainwrightHC Wainwright started coverage on Cardiol Therapeutics in a report on Monday. They issued a "buy" rating and a $9.00 price objective on the stock.April 22, 2024 | marketbeat.comCRDL Stock Earnings: Cardiol Therapeutics Beats EPS for Q4 2023April 2, 2024 | investorplace.comCardiol Therapeutics surpasses enrollment goals, prepares for topline resultsApril 2, 2024 | proactiveinvestors.comCardiol Therapeutics Inc. (NASDAQ:CRDL) Forecasted to Post FY2024 Earnings of ($0.31) Per ShareCardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Analysts at Leede Jones Gab boosted their FY2024 EPS estimates for Cardiol Therapeutics in a note issued to investors on Monday, March 25th. Leede Jones Gab analyst D. Loe now anticipates that the company will earn ($0.31) per share for theMarch 28, 2024 | marketbeat.comCardiol Therapeutics (CRDL) to Release Earnings on TuesdayCardiol Therapeutics (NASDAQ:CRDL) will be releasing earnings on Tuesday, March 26, Yahoo Finance reports.March 25, 2024 | marketbeat.comClosing Bell: Cardiol Therapeutics Inc Purchase WT down on Friday (CRDL-WT-A)March 16, 2024 | theglobeandmail.comShort Interest in Cardiol Therapeutics Inc. (NASDAQ:CRDL) Increases By 108.1%Cardiol Therapeutics Inc. (NASDAQ:CRDL - Get Free Report) was the recipient of a significant increase in short interest during the month of February. As of February 29th, there was short interest totalling 361,100 shares, an increase of 108.1% from the February 14th total of 173,500 shares. Approximately 0.6% of the company's stock are sold short. Based on an average daily volume of 335,900 shares, the short-interest ratio is currently 1.1 days.March 13, 2024 | marketbeat.comCardiol Therapeutics Stock (NASDAQ:CRDL), Short Interest ReportFebruary 22, 2024 | benzinga.comCardiol Therapeutics wraps up patient enrollment for Phase II open label studyFebruary 21, 2024 | proactiveinvestors.comCardiol CEO David Elsley unpacks FDA Orphan Drug Designation for CardiolFebruary 16, 2024 | proactiveinvestors.comCardiol Therapeutics receives orphan drug status for its lead drug...February 15, 2024 | proactiveinvestors.comOrphan Drug Designation Sends Shares of this Dual-Listed Life Science Therapy Company SoaringFebruary 15, 2024 | theglobeandmail.comCardiol stock rallies 28% on FDA orphan drug status for CardiolRxFebruary 15, 2024 | msn.comCardiol Therapeutics receives orphan drug status for its lead drug candidateFebruary 15, 2024 | proactiveinvestors.comShort Interest in Cardiol Therapeutics Inc. (NASDAQ:CRDL) Drops By 9.0%Cardiol Therapeutics Inc. (NASDAQ:CRDL - Get Free Report) was the recipient of a significant decrease in short interest in January. As of January 15th, there was short interest totalling 119,600 shares, a decrease of 9.0% from the December 31st total of 131,500 shares. Approximately 0.2% of the shares of the company are sold short. Based on an average trading volume of 144,800 shares, the days-to-cover ratio is presently 0.8 days.January 30, 2024 | marketbeat.comCardiol Therapeutics Inc Class A CRDLJanuary 9, 2024 | morningstar.comCardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute MyocarditisJanuary 9, 2024 | finance.yahoo.comClosing Bell: Cardiol Therapeutics Inc Purchase WT down on Tuesday (CRDL-WT-A)December 18, 2023 | theglobeandmail.com Get Cardiol Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRDL and its competitors with MarketBeat's FREE daily newsletter. Email Address Has Trump Finally Gone Too Far? (Ad)Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news. Register For The Webinar To Discover CRDL Media Mentions By Week CRDL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRDL News Sentiment▼0.430.55▲Average Medical News Sentiment CRDL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRDL Articles This Week▼31▲CRDL Articles Average Week Get Cardiol Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRDL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ANAB News HUMA News OCS News IGMS News PRTC News ALT News SANA News ATXS News TERN News GLUE News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRDL) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiol Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiol Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRDL Stock Alerts